Skip to main content
Open Forum Infectious Diseases logoLink to Open Forum Infectious Diseases
. 2018 Nov 26;5(Suppl 1):S504–S505. doi: 10.1093/ofid/ofy210.1438

1782. Guideline-Discordant Carbapenem Prescribing Policies at a Large, Urban Hospital in Manila, Philippines

Kaitlin Mitchell 1, Nasia Safdar 2, Cybele Lara Abad 3
PMCID: PMC6253409

Abstract

Background

Hospital antimicrobial stewardship programs are critical in countries such as the Philippines, where antibiotic-resistant infections are highly prevalent. At our institution, a Prior Antimicrobial Restriction Approval (PARA) is required for noninfectious disease specialists to prescribe carbapenems. PARA request forms include specification of empiric or definitive therapy based on diagnostic tests. Recommended duration of therapy is typically 3 days for empiric use and 7 days for definitive, with possible extension upon specialist approval.

Methods

The study took place at an 800-bed tertiary hospital in Manila, Philippines. Using retrospective chart review, patients with a PARA request for carbapenems between January and December 2016 were identified. Information on patient demographics, hospital stay, infection, treatment, and outcomes was collected using the hospital’s online record system. Carbapenem use was scored as concordant or discordant based on guidelines of the Infectious Diseases Society of America: de-escalation based on culture data, length of carbapenem therapy, and/or consultation with an Infectious Disease Specialist.

Results

Of 183 patients on carbapenem therapy, 56 (31%) were classified as definitive and 127 (69%) were empiric (Table 1). In addition, 56 (44%) of the patients on empiric therapy were found to be guideline-discordant. The primary reason for discordance was failure to de-escalate the carbapenem following culture results (80% of cases with empiric prescriptions).

Table 1:

Characteristics of patient cases with requests for carbapenem therapy

Cases with PARA requests Total n = 183 Definitive, n = 56 Empiric, n = 127 P-value
Age (median, years) 75.5 78.4 72.7 0.09
Gender (% male) 44.8 53.6 40.9 0.11
Duration of carbapenem therapy (days) 6.5 7.0 5.0 0.13
Mortality (% deceased) 23.0 17.9 25.2 0.28
Recurrent infection (%) 7.65 3.57 9.45 0.17
Guideline-based carbapenem therapy (% concordant) 59.0 69.6 54.3 0.05

Conclusion

Patients who were prescribed carbapenems empirically were more likely to have overall discordant therapy, which was often due to unnecessarily long antibiotic courses or failure to revise treatment based on laboratory data. Interventions that focus on drug de-escalation and incorporation of laboratory data into prescription choice should be implemented.

Disclosures

All authors: No reported disclosures.

Session: 216. Antimicrobial Stewardship: Global Perspectives

Saturday, October 6, 2018: 12:30 PM


Articles from Open Forum Infectious Diseases are provided here courtesy of Oxford University Press

RESOURCES